Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report

Neuro-Oncology

Volumn 18, Issue , 2016, Pages ii1-ii12

  Armstrong, Terri S ^a   Bishof, Allison M ^b   Brown, Paul D ^c   Klein, Martin ^d   Taphoorn, Martin J B ^d,e   Theodore Oklota, Christina ^f  

^a UNIVERSITY OF TEXAS   (United States)

^b Patient Advocate   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MEDICAL CENTER HAAGLANDEN   (Netherlands)

^f GENENTECH INC   (United States)

Author keywords

clinical outcomes assessment; glioblastoma; glioma; outcomes; signs and symptoms

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; STEROID; TEMOZOLOMIDE;

ARTICLE; BRAIN EDEMA; BRAIN TUMOR; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL OUTCOMES ASSESSMENT; FUNCTIONAL STATUS; GLIOBLASTOMA; HUMAN; INCREASED APPETITE; NONHUMAN; OUTCOME ASSESSMENT; PRIMARY TUMOR; QUALITY OF LIFE; SIDE EFFECT; SLEEP DISORDER; SYMPTOM; TREATMENT RESPONSE; ANIMAL; BRAIN MAPPING; BRAIN NEOPLASMS; GLIOMA; PATHOLOGY; PROCEDURES;

ANIMALS; BRAIN MAPPING; BRAIN NEOPLASMS; GLIOBLASTOMA; GLIOMA; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE;

EID: 84965101732     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov267     Document Type: Article

References (109)

1. Armstrong TS, Gilbert MR. Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients. Curr Treat Options Oncol. 2014;15(4):519-528.
2. Quinn T, Ostrom HG, Liao P, et al. CBTRUS Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16(suppl 4):iv1-iv63.
3. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
4. Armstrong TS, Cohen MZ, Eriksen LR, Hickey JV. Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors. J Nurs Scholarsh. 2004;36(3): 197-206.
5. Bradley S, Sherwood PR, Donovan HS, et al. I could lose everything: understanding the cost of a brain tumor. J Neurooncol. 2007;85(3): 329-338.
6. Fobair P, Mackworth N, Varghese A, Prados M. Quality of life issues among 200 brain tumor patients treated at the University of California in San Francisco, interviewed 1988. Paper presented at: Brain Tumor Conference: a living resource guide. San Francisco, California, March 3-5, 1990.
7. Armstrong TS, Vera-Bolanos E, Gilbert MR. Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project. Cancer. 2011;117(22):5133-5141.
8. Strang S, Strang P. Spiritual thoughts, coping and 'sense of coherence' in brain tumour patients and their spouses. Palliat Med. 2001;15(2):127-134.
9. Salander P, Spetz A. How do patients and spouses deal with the serious facts of malignant glioma? Palliat Med. 2002;16(4):305-313.
10. Woehrer A, Bauchet L, Barnholtz-Sloan JS. Glioblastoma survival: has it improved? Evidence from population-based studies. Curr Opin Neurol. 2014;27(6):666-674.
11. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
12. Robin AM, Walbert T, Mikkelsen T, et al. Through the patient's eyes: the value of a comprehensive brain tumor center. J Neurooncol. 2014;119(3):465-472.
13. Ellingson BM, Bendszus M, Boxerman J, et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015;17(9):1188-1198.
14. Russell B, Collins A, Dally M, et al. Living longer with adult high-grade glioma: setting a research agenda for patients and their caregivers. J Neurooncol. 2014;120(1):1-10.
15. Moore G, Collins A, Brand C, et al. Palliative and supportive care needs of patients with high-grade glioma and their carers: a systematic review of qualitative literature. Patient Educ Couns. 2013;91(2):141-153.
16. McConigley R, Halkett G, Lobb E, Nowak A. Caring for someone with high-grade glioma: a time of rapid change for caregivers. Palliat Med. 2010;24(5):473-479.
17. Kinno R, Ohta S, Muragaki Y, Maruyama T, Sakai KL. Left frontal glioma induces functional connectivity changes in syntaxrelated networks. Springerplus. 2015;4:317.
18. Cipolotti L, Healy C, Chan E, et al. The impact of different aetiologies on the cognitive performance of frontal patients. Neuropsychologia. 2015;68:21-30.
19. Halkett GK, Lobb EA, Rogers MM, et al. Predictors of distress and poorer quality of life in High Grade Glioma patients. Patient Educ Couns. 2015;98(4):525-532.
20. Osoba D, Aaronson NK, Muller M, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancerspecific questionnaires. Qual Life Res. 1996;5(1):139-150.
21. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer. 1995;75(5):1151-1161.
22. Armstrong TS, Cohen MZ, Eriksen L, Cleeland C. Content validity of self-report measurement instruments: an illustration from the development of the Brain Tumor Module of the M.D. Anderson Symptom Inventory. Oncol Nurs Forum. 2005;32(3):669-676.
23. Armstrong TS, Mendoza T, Gning I, et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol. 2006;80(1):27-35.
24. Lai JS, Jensen SE, Beaumont JL, et al. Development of a symptom index for patients with primary brain tumors. Value Health. 2014; 17(1):62-69.
25. Mauer M, Bottomley A, Taphoorn MJ. Evaluating health-related quality of life and symptom burden in brain tumour patients: instruments for use in experimental trials and cilnical practice. Curr Opin Neurol. 2008;21(6):745-753.
26. Frankel SA, German WJ. Glioblastoma multiforme; review of 219 cases with regard to natural history, pathology, diagnostic methods, and treatment. J Neurosurg. 1958;15(5):489-503.
27. Jelsma R, Bucy PC. The treatment of glioblastoma multiforme of the brain. J Neurosurg. 1967;27(5):388-400.
28. Roth JG, Elvidge AR. Glioblastoma multiforme: a clinical survey. J Neurosurg. 1960;17:736-750.
29. Krouwer HG, van Duinen SG, Kamphorst W, van der Valk P, Algra A. Oligoastrocytomas: a clinicopathological study of 52 cases. J Neurooncol. 1997;33(3):223-238.
30. Yeh SA, Leung SW, Sun LM, Wang CJ, Fang FM, Chen HC. Postoperative radiotherapy for supratentorial malignant gliomas. J Neurooncol. 1999;42(2):183-187.
31. Mukand JA, Blackinton DD, Crincoli MG, Lee JJ, Santos BB. Incidence of neurologic deficits and rehabilitation of patients with brain tumors. Am J Phys Med Rehabil. 2001;80(5):346-350.
32. Polin RS, Marko NF, Ammerman MD, et al. Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres. J Neurosurg. 2005;102(2): 276-283.
33. Laws ER, Parney IF, HuangW, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99(3): 467-473.
34. Collins A, Sundararajan V, Brand CA, et al. Clinical presentation and patterns of care for short-term survivors of malignant glioma. J Neurooncol. 2014;119(2):333-341.
35. Tucha O, Smely C, Preier M, Lange KW. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery. 2000;47(2):324-333; discussion 333-324.
36. Molassiotis A, Wilson B, Brunton L, Chaudhary H, Gattamaneni R, McBain C. Symptom experience in patients with primary brain tumours: a longitudinal exploratory study. Eur J Oncol Nurs. 2010;14(5):410-416.
37. Johansson E, Wilson B, Brunton L, Tishelman C, Molassiotis A. Symptoms before, during, and 14 months after the beginning of treatment as perceived by patients with lymphoma. Oncol Nurs Forum. 2010;37(2):E105-E113.
38. Taphoorn MJ, Claassens L, Aaronson NK, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46(6): 1033-1040.
39. Ottenhausen M, Krieg SM, Meyer B, Ringel F. Functional preoperative and intraoperative mapping and monitoring: increasing safety and efficacy in glioma surgery. Neurosurg Focus. 2015;38(1):E3.
40. Freyschlag CF, Duffau H. Awake brain mapping of cortex and subcortical pathways in brain tumor surgery. J Neurosurg Sci. 2014;58(4):199-213.
41. Sutton K. The impact on quality of life for people with brain tumours of entering a research trial involving new anti-cancer agents. Eur J Oncol Nurs. 2013;17(4):396-401.
42. Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. J Clin Oncol. 2014;32(6):535-541.
43. Armstrong TS, Wefel JS, Wang M, et al. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2013;31(32):4076-4084.
44. Taphoorn MJ, Henriksson R, Bottomley A, et al. Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. J Clin Oncol. 2015;33(19):2166-2175.
45. Bag AK, Kim H, Gao Y, et al. Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas. J Neurooncol. 2015;122(3): 585-593.
46. Jiang X, Engelbach JA, Yuan L, et al. Anti-VEGF antibodies mitigate the development of radiation necrosis in mouse brain. Clin Cancer Res. 2014;20(10):2695-2702.
47. Wefel JS, Cloughesy T, Zazzali JL, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011;13(6):660-668.
48. Galicich JH, French LA. Use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery. Am Pract Dig Treat. 1961;12:169-174.
49. Galicich JH, French LA, Melby JC. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. J Lancet. 1961;81:46-53.
50. Ryan R, Booth S, Price S. Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neurooncol. 2012; 106(3):449-459.
51. Weissman DE, Dufer D, Vogel V, Abeloff MD. Corticosteroid toxicity in neuro-oncology patients. J Neurooncol. 1987;5(2): 125-128.
52. Sturdza A, Millar BA, Bana N, et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer. 2008;16(9):1041-1048.
53. Armstrong TS, Vera-Bolanos E, Acquaye AA, Gilbert MR, Ladha H, Mendoza T. The symptom burden of primary brain tumors: evidence for a core set of tumor and treatment related symptoms. Neuro Oncol. 2016;18(2):252-260.
54. Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol. 2003;5(2):89-95.
55. Armstrong TS, Vera-Bolanos E, Gning I, et al. The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. Cancer. 2011; 117(14):3222-3228.
56. Quinten C, Coens C, Mauer M, et al.: EORTC Clinical Groups. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual m=patient data from EORTC clinical trials. Lancet Oncol. 2009;10(9):865-871.
57. Peters KB, West MJ, Hornsby WE, et al. Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients. J Neurooncol. 2014;120(3):499-506.
58. Boele FW, Rooney AG, Grant R, Klein M. Psychiatric symptoms in glioma patients: from diagnosis to management. Neuropsychiatr Dis Treat. 2015;11:1413-1420.
59. Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol. 2002; 57(1):41-49.
60. Litofsky NS, Farace E, Anderson F Jr, Meyers CA, Huang W, Laws ER Jr. Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery. 2004;54(2): 358-366; discussion 366-357.
61. Mainio A, Hakko H, Niemela A, Koivukangas J, Rasanen P. Depression and functional outcome in patients with brain tumors: a population-based 1-year follow-up study. J Neurosurg. 2005;103(5):841-847.
62. Acquaye AA, Vera-Bolanos E, Armstrong TS, Gilbert MR, Lin L. Mood disturbance in glioma patients. J Neurooncol. 2013; 113(3):505-512.
63. Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin EC. Prospective study of neuropsychologic testing and quality-oflife assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys. 2003;55(4):992-999.
64. Wellisch DK, Kaleita TA, Freeman D, Cloughesy T, Goldman J. Predicting major depression in brain tumor patients. Psychooncology. 2002;11(3):230-238.
65. Mainio A, Hakko H, Niemela A, Salo J, Koivukangas J, Rasanen P. Level of obsessionality among neurosurgical patients with a primary brain tumor. J Neuropsychiatry Clin Neurosci. 2005; 17(3):399-404.
66. Andrewes DG, Kaye A, Murphy M, et al. Emotional and social dysfunction in patients following surgical treatment for brain tumour. J Clin Neurosci. 2003;10(4):428-433.
67. Boele FW, Douw L, Reijneveld JC, et al. Health-related quality of life in stable, long-term survivors of low-grade glioma. J Clin Oncol. 2015;33(9):1023-1029.
68. Cavers D, Hacking B, Erridge SE, Kendall M, Morris PG, Murray SA. Social, psychological and existential well-being in patients with glioma and their caregivers: a qualitative study. CMAJ. 2012; 184(7):E373-E382.
69. Janda M, Steginga S, Dunn J, Langbecker D, Walker D, Eakin E. Unmet supportive care needs and interest in services among patients with a brain tumour and their carers. Patient Educ Couns. 2008;71(2):251-258.
70. Lucas MR. Psychosocial implications for the patient with a high-grade glioma. J Neurosci Nurs. 2010;42(2):104-108.
71. Sterckx W, Coolbrandt A, Dierckx de Casterle B, et al. The impact of a high-grade glioma on everyday life: a systematic review from the patient's and caregiver's perspective. Eur J Oncol Nurs. 2013; 17(1):107-117.
72. Filley CM, Kleinschmidt-DeMasters BK. Neurobehavioral presentations of brain neoplasms. West J Med. 1995;163(1): 19-25.
73. Shah AH, Gordon CE, Bregy A, Shah N, Komotar RJ. Considering iatrogenic psychosis after malignant glioma resection. BMJ Case Rep. 2014. doi: 10.1136/bcr-2013-201318.
74. Habets EJ, Kloet A, Walchenbach R, Vecht CJ, Klein M, Taphoorn MJ. Tumour and surgery effects on cognitive functioning in high-grade glioma patients. Acta Neurochir (Wien). 2014; 156(8):1451-1459.
75. Gehrke AK, Baisley MC, Sonck AL, Wronski SL, Feuerstein M. Neurocognitive deficits following primary brain tumor treatment: systematic review of a decade of comparative studies. J Neurooncol. 2013;115(2):135-142.
76. Kerrigan S, Erridge S, Liaquat I, Graham C, Grant R. Mental incapacity in patients undergoing neuro-oncologic treatment: a cross-sectional study. Neurology. 2014;83(6):537-541.
77. Talacchi A, Santini B, Savazzi S, Gerosa M. Cognitive effects of tumour and surgical treatment in glioma patients. J Neurooncol. 2011;103(3):541-549.
78. Kayl AE, Meyers CA. Does brain tumor histology influence cognitive function? Neuro Oncol. 2003;5(4):255-260.
79. Klein M, Taphoorn MJ, Heimans JJ, et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol. 2001;19(20):4037-4047.
80. Bosma I, Vos MJ, Heimans JJ, et al. The course of neurocognitive functioning in high-grade glioma patients. Neuro Oncol. 2007; 9(1):53-62.
81. Hom J, Reitan RM. Neuropsychological correlates of rapidly vs. slowly growing intrinsic cerebral neoplasms. J Clin Neuropsychol. 1984;6(3):309-324.
82. Scheibel RS, Meyers CA, Levin VA. Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol. 1996;30(1):61-69.
83. Klein M, Duffau H, De Witt Hamer PC. Cognition and resective surgery for diffuse infiltrative glioma: an overview. J Neurooncol. 2012;108(2):309-318.
84. de Groot M, Douw L, Sizoo EM, et al. Levetiracetam improves verbal memory in high-grade glioma patients. Neuro Oncol. 2013;15(2):216-223.
85. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012;12(3):267-275.
86. Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3(3):159-168.
87. Mitchell AJ, Kemp S, Benito-Leon J, Reuber M. The influence of cognitive impairment on health-related quality of life in neurological disease. Acta Neuropsychiatr. 2010;22(1):2-13.
88. Giovagnoli AR, Silvani A, Colombo E, Boiardi A. Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry. 2005;76(4):562-568.
89. Catt S, Chalmers A, Fallowfield L. Psychosocial and supportivecare needs in high-grade glioma. Lancet Oncol. 2008;9(9):884-891.
90. Armstrong TS, Gilbert MR. Practical strategies for management of fatigue and sleep disorders in people with brain tumors. Neuro Oncol. 2012;14(Suppl 4):iv65-iv72.
91. Lin L, Acquaye AA, Vera-Bolanos E, Cahill JE, Gilbert MR, Armstrong TS. Validation of the Mishel's uncertainty in illness scale-brain tumor form (MUIS-BT). J Neurooncol. 2012;110(2):293-300.
92. Lovely MP, Miaskowski C, Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiformae. Oncol Nurs Forum. 1999;26(5):921-925.
93. Armstrong TS, Cron SG, Bolanos EV, Gilbert MR, Kang DH. Risk factors for fatigue severity in primary brain tumor patients. Cancer. 2010;116(11):2707-2715.
94. Valko PO, Siddique A, Linsenmeier C, Zaugg K, Held U, Hofer S. Prevalence and predictors of fatigue in glioblastoma: a prospective study. Neuro Oncol. 2015;17(2):274-281.
95. Powell C, Guerrero D, Sardell S, et al. Somnolence syndrome in patients receiving radical radiotherapy for primary brain tumours: a prospective study. Radiother Oncol. 100(1):131-136.
96. Osoba D, Brada M, Prados MD, Yung WK. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro Oncol. 2000;2(4):221-228.
97. Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol. 2000;18(7): 1481-1491.
98. Brown PD, Jensen AW, Felten SJ, et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol. 2006;24(34):5427-5433.
99. Brown PD, Ballman KV, Rummans TA, et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol. 2006;76(3):283-291.
100. Faithfull S, Brada M. Somnolence syndrome in adults following cranial irradiation for primary brain tumours. Clin Oncol (R Coll Radiol). 1998;10(4):250-254.
101. Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas. Epilepsia. 2013;54(suppl 9):12-17.
102. Kerkhof M, Dielemans JC, van Breemen MS, et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol. 2013;15(7):961-967.
103. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421-430.
104. Luchi T, Hasegawa Y, Kawasaki K, Sakaida T. Epilepsy in patients with gliomas: incidence and control of seizures. J Clin Neursci. 2015;22(1):87-91.
105. Michelucci R, Pasini E, Meletti S, et al. Epilepsy in primary cerebral tumors: the characteristics of epilepsy at the onset (results from the PERNO study-Project of Emilia Romagna Region on Neuro-Oncology). Epilepsia. 2013;54:86-91.
106. Chaichana KL, Parker SL, Olivi A, Quinones-Hinojosa A. Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article. J Neurosurg. 2009;111(2):282-292.
107. Armstrong TS, Kanusky JT, Gilbert MR. Seize the moment to learn about epilepsy in people with cancer. Clin J Oncol Nurs. 2003; 7(2):163-169.
108. Koekkoek JA, Kerkhof M, Dirven L, Heimans JJ, Reijneveld JC, Taphoorn MJ. Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review. Neuro Oncol. 2015;17(7):924-934.
109. Ruda R, Bello L, Duffau H, Soffietti R. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol. 2012;14:(suppl 4):iv55-iv64.